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Five antiepileptic drugs have been marketed in the last decade. We report here a retrospective study of patients attending our
unit who were prescribed one of the new antiepileptic drugs. All these patients had refractory localization related epilepsy and
had failed to respond to a first-line drug.
The drugs had a different profile of side-effects but topiramate (42%) was the most common drug to be withdrawn due to
side-effects as compared with tiagabine (26%), vigabatrin (16%), gabapentin (16%), and lamotrigine (15%).
With regard to efficacy, 31% of the patients receiving gabapentin had a greater than 50% reduction in seizures compared with
lamotrigine (25%), topiramate (20%), vigabatrin (19%) and tiagabine (11%). The number of patients remaining seizure free
with gabapentin was 8% whilst for lamotrigine this was 5%, vigabatrin 5%, topiramate 1% and tiagabine 4%.
In conclusion, all these five antiepileptic drugs are useful in treating refractory localization related epilepsy.
c© 2000 BEA Trading Ltd
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INTRODUCTION
A number of new antiepileptic drugs have been mar-
keted in the last few years. It is difficult from clinical
trials to compare efficacy and tolerability. This is com-
pounded by the fact that most patients in these trials
have been referred to tertiary epilepsy centres having
refractory epilepsy and have already been tried on the
usual first-line agents. There are no prospective studies
that have compared the drugs head to head. A meta-
analysis of double blind trials1 has shown that there
are no major differences between these drugs with re-
gard to efficacy and tolerability.
We have audited retrospectively the outcome for pa-
tients who were treated with one of the new antiepilep-
tic drugs namely vigabatrin, lamotrigine, gabapentin,
topiramate or tiagabine. The study looked at their effi-
cacy and tolerability in a group of patients with refrac-
tory localization related epilepsy.
MATERIALS AND METHODS
Patients were identified retrospectively by looking
through case notes. All patients had localization re-
lated epilepsy that was refractory to their current
antiepileptic medications and were already taking be-
tween one to three background antiepileptic drugs.
The patients were commenced on one of the five
new antiepileptic drugs in our unit by one consul-
tant (PMC). The time period during which the patients
were treated with one or more of the new antiepilep-
tic drugs was from March 1990 to January 1999. The
patients kept a record of their seizure numbers in a di-
ary provided by our unit. In the subsequent follow-
up visits the patients brought their diaries back and
any change in seizure frequency or any reported side-
effects were documented in the case notes. Changes in
seizure frequency were quantified as either seizure free
or a greater than 50% reduction or between 25 to 50%
decrease of seizure numbers. A note was also made
if they reported an increase in their seizures. Patients
who had a greater than 50% reduction of their seizures
for at least 6 months have been included to calcu-
late efficacy. The data for topiramate and tiagabine
include patients from open label phase of trials and
after licensing. There were 70 patients on topiramate
of which 37 were from an open label drug trial and
33 were put on the drug after licensing whilst 77 pa-
tients taking tiagabine were part of an open label drug
study (initially double blinded) and 11 patients re-
ceived the drug after this was marketed.
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Table 1: Patient demographics.
Gabapentin Lamotrigine Vigabatrin Topiramate Tiagabine
Total patients 146 122 37 70 88
Men 45% 43% 49% 47% 48%
Women 55% 57% 51% 53% 52%
Age (years)
Range 16–75 16–77 20–65 16–75 20–64
Mean ± SD 37.23± 12.02 35.90± 12.94 36.75± 10.29 38.47± 13.15 37.98± 10.68
Onset (Years) of
epilepsy
Range 0–71 0–60 0–48 0–58 0–50
Mean ± SD 17.35± 13.81 15.02± 13.50 12.35± 10.21 15.16± 12.92 14.22± 11.94
Table 2: Previously used new drugs.
Gabapentin Lamotrigine Vigabatrin Topiramate Tiagabine
n = 146 n = 122 n = 37 n = 70 n = 88
Prior drugs
Range 1–11 1–11 1–10 2–14 1–14
Mean ± SD 4.19± 2.1 4.2± 2.0 4.7± 2.14 5.87± 2.26 5.58± 2.38
Gabapentin — 21% 19% 47% 33%
Lamotrigine 36% — 35% 44% 50%
Vigabatrin 27% 21% — 30% 44%
Topiramate 5% 6% 5% — 19%
Tiagabine 12% 11% 5% 16% —
Trial drugs 12% 16% 5% 23% 18%
Percentage of patients
trying at least
one new drug 53% 48% 38% 91% 78%
Table 3: Concurrent AED therapy.
Gabapentin Lamotrigine Vigabatrin Topiramate Tiagabine
n = 146 n = 122 n = 37 n = 70 n = 88
Carbamazepine 52% 37% 73% 70% 58%
Carbamazepine
Retard 12% 18% 11% 14% 15%
Phenytoin 18% 6% 19% 19% 7%
Sodium Valproate 27% 10% 32% 20% 26%
Vigabatrin 3% 2% — 7% 15%
Lamotrigine 8% — 3% 13% 22%
Gabapentin — 2% 0 16% 11%
Clobazam 3% 4% 5% 9% 7%
Topiramate 1% 1% 0 — 9%
Tiagabine 1% 2% 2% 0 —
In our center some patients were started on lamotrig-
ine and topiramate for idiopathic generalized epilepsy
and some newly diagnosed patients received lamotrig-
ine as a monotherapy. These patients were excluded
for analysis.
RESULTS
The demographic data is summarized in Table 1. Pre-
vious new antiepileptic drug therapy prior to start-
ing one of these five antiepileptics is shown in Ta-
ble 2. Many patients had also tried trial medica-
tions such as oxcarbazepine, remacemide, losigamone
and levetiracetam. Table 3 highlights the background
antiepileptic therapy patients were taking at the time of
commencement of one of these five medications. Fig-
ure 1 shows the number of background antiepileptic
drugs the patients were taking when they were com-
menced on one of these five new antiepileptic drug.
The dose, duration of taking and percentage of pa-
tients continuing therapy with one of the five med-
ications are summarized in Table 4. Figures 2, 3
and 4 show the percentage of patients having a greater
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Fig. 1: Number of background AEDs.
Table 4: Dose and efficacy.
Gabapentin Lamotrigine Vigabatrin Topiramate Tiagabine
n = 146 n = 122 n = 37 n = 70 n = 88
Years of usage since 1993 since 1991 since 1990 since 1992 since 1992
Dose (mg)
Range 300–4800 25–800 1000–4500 25–900 10–65
Mean ± SD 2207.58± 996 293.59± 165.75 2459.45± 1055.09 342.85± 219.58 40.22± 16.11
Duration (months)
of treatment
Range 0–40.92 0.06–58.65 0.09–83.58 0.23–51.30 0.23–75.49
Mean ± SD 12.7± 10.9 14.31± 15.08 28.61± 26.25 13.54± 14.43 18.6± 23.93
Withdrawal of drug
from lack of efficacy 25% 16% 46% 30% 30%
Percentage of patients
continuing therapy 51% 60% 38% 47% 39%
than 50% reduction in seizures, seizure free and
greater than 25% worsening of seizures, respectively.
In this study, 31% of the patients on gabapentin had
a >50% decrease of seizure numbers over at least a
6-month period compared with 25% on lamotrigine
and 19% on vigabatrin with 8%, 6% and 5% remain-
ing seizure free, respectively. Out of 37 patients started
on vigabatrin, 46% withdrew the drug from lack of ef-
ficacy as compared with 25% on gabapentin and 16%
on lamotrigine. Topiramate was effective in reducing
the number of fits in 20% of the patients by greater
than 50%, with 1% remaining seizure free whilst only
a small number (11%) had a greater than 50% de-
crease after commencing tiagabine therapy and 3% re-
mained seizure free. Although gabapentin was added
to a background antiepileptic drug, in 10 patients these
drugs were withdrawn and they continued gabapentin
as monotherapy. Two of these patients continued to
remain seizure free whilst the remaining eight had a
greater than 50% reduction of fit frequency.
Table 5 lists the side-effects of the five drugs as re-
ported by the patients. The side-effect profile differed
between the medications. Rash was the main problem
encountered by patients starting lamotrigine (5%) and
this led to cessation of therapy. Drowsiness was a com-
mon side-effect of all the drugs but lamotrigine was
the least likely to have caused this. Dizziness was a
significant problem with gabapentin and even more so
with tiagabine and this commonly led to withdrawal of
these two drugs. This side-effect was seen in the initial
stages when gabapentin was started at doses usually
between 400 to 1200 mg/day and with tiagabine be-
tween 10 to 20 mg/day. Dizziness also occurred in pa-
tients with lamotrigine, vigabatrin and topiramate but
rarely ever necessitated withdrawal of the drugs.
Psychiatric side-effects were a significant problem
with both vigabatrin (16%) and topiramate (42%)
leading to withdrawal of these two medications. De-
pression was the commonest psychiatric manifesta-
tion with vigabatrin but topiramate caused depression
and hallucinations with psychotic symptoms. Whilst
vigabatrin-induced depression warranted only with-
drawal of the drug, two patients who developed de-
pression and six patients with psychotic symptoms
54 P. K. Datta & P. M. Crawford
>50% reduction in
seizures 19%
0%
5%
10%
15%
20%
25%
30%
35%
25% 31% 20% 11%
Vigabatrin Lamotrigine Gabapentin Topiramate Tiagabine
Fig. 2: Efficacy of the new antiepileptic drugs—percentage of patients with a greater than 50% reduction in seizures.
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Fig. 3: Percentage of patients seizure free on one of the new AEDs.
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Fig. 4: Percentage of patients with a deterioration in seizures.
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Table 5: Comparison of side-effects.
Gabapentin Lamotrigine Vigabatrin Topiramate Tiagabine
n = 146 n = 122 n = 37 n = 70 n = 88
Rash 0 5% 0 0 0
Drowsiness 11% 7% 16% 24% 16%
Dizziness 5% 6% 3% 9% 23%
Cognitive side-effects 2% 0.8% 3% 33% 1%
Weight gain 3% 0 0 0 0
Weight loss 0 0 0 17% 0
Diplopia 5% 7% 3% 1% 4%
Headache 7% 4% 3% 13% 1%
Psychiatric side-effects 4% 3% 16% 41% 9%
Withdrawal of drug
due to side-effects 16% 15% 16% 42% 26%
on topiramate needed hospitalization and referral to a
psychiatrist. None of the patients on these two drugs
had a previous psychiatric history. Patients on topi-
ramate had a normal EEG during these events and
the side-effects were reversed after stopping the drug.
Tiagabine was also associated with psychiatric side-
effects in eight patients but these consisted of mood-
iness and irritability and were reversed after the drug
was stopped. Two patients on lamotrigine and one pa-
tient on gabapentin had psychotic symptoms (hallu-
cinations) which stopped within a few days of with-
drawal therapy and did not need admission or referral
to a psychiatrist.
Cognitive side-effects and weight loss were also re-
ported by a high percentage of the patients taking topi-
ramate. Many of them had to stop the drug. Apart from
dizziness and drowsiness, 7% of the patients taking
tiagabine complained of nausea and feeling generally
unwell leading to cessation of therapy.
DISCUSSION
Vigabatrin, lamotrigine, gabapentin, topiramate and
tiagabine have been licensed at different times over
the last 10 years for the treatment of epilepsy. Lam-
otrigine and topiramate are effective for both idio-
pathic generalized and localization related epilepsy
whilst the other three are effective for localization re-
lated epilepsy. All five drugs have been shown to be
effective in double blind trials. Meta analysis1 of pub-
lished and unpublished trials with these drugs showed
an overlapping of the confidence intervals, reflecting
very little difference between them.
Our study is not prospective or randomized and
some bias may have occurred in the choice of drug
allocated. However, the groups appeared similar look-
ing at the demographic data with regards to seizure
history but they differed in the number of new AEDs
taken previously, reflecting the intractable nature of
the seizures in these patients and the different times
when they were licensed.
A retrospective survey2 looking at the usage of viga-
batrin, lamotrigine and gabapentin used time to with-
drawal to show perceived lack of efficacy. The survey
showed that gabapentin (33.5%) was more likely to be
discontinued than either lamotrigine (23.3%) or viga-
batrin (32.8%) due to lack of efficacy and that lamot-
rigine (13%) was the least likely to have been with-
drawn due to adverse events. In our study, vigabatrin
(46%) was the most commonly withdrawn drug due to
lack of efficacy and lamotrigine (16%) was the least
likely whilst topiramate was more likely to have been
withdrawn due to side-effects compared with vigaba-
trin, lamotrigine and gabapentin, all of which had sim-
ilar withdrawal figures.
Another study by Schapel and Chadwick3 compar-
ing patients on lamotrigine and vigabatrin, reported
that 43% on lamotrigine had a greater than 50% de-
crease of seizure frequency whilst 37% on vigaba-
trin had a similar benefit with 6% on lamotrigine and
7% on vigabatrin remaining seizure free. Our effi-
cacy figures are lower but a similar percentage became
seizure free. Lamotrigine and vigabatrin in the Schapel
study was continued by 67% and 51%, respectively.
Lamotrigine-related side-effects leading to withdrawal
were seen in 15% of the patients as compared with
25% on vigabatrin (8% had psychiatric side-effects).
The number of patients in our study stopping the drug
due to side-effects were identical for lamotrigine but
lower for vigabatrin. However, in our study, psychi-
atric side-effects (16%) were commoner in patients
taking vigabatrin.
A retrospective surveillance study of lamotrigine
in patients over the age of 12 years with refractory
epilepsy was reported from the Netherlands4. A to-
tal of 624 patients were treated with lamotrigine either
as monotherapy or as an add-on therapy. This study
found that 76% were still continuing to take lamot-
rigine after 1 year. There was a ≥50% reduction in
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seizures in 32%, 6% remaining seizure free for at least
3 months. In our study, the percentage of patients be-
coming seizure free on lamotrigine was similar but
fewer had a greater than 50% reduction in seizures and
a lower percentage continued lamotrigine.
Morris5 reported the results of a larger retrospec-
tive analysis of adjunctive therapy with gabapentin
in clinical practice. This involved a random sample
of patients in a clinical practice. Data was collected
for 100 consecutive patients with partial seizures who
had received add-on therapy with gabapentin. In this
study, 43% of the patients discontinued gabapentin,
17% from side-effects and another 17% due to lack
of efficacy. Of the patients, 72% had a >50% re-
duction of seizures and 23% had a ≥75% decrease.
Gabapentin was continued by 57% of which 5% con-
tinued the drug as monotherapy. Those patients who
had a lower seizure frequency tended to respond better
to gabapentin on initiation of therapy compared with
those who had a higher seizure frequency. The high
percentage of responders was felt to be due to the fact
that many patients had a significantly lower monthly
seizure frequency than those did in the majority of
the clinical trials and a high dose of gabapentin were
used. In our study, the percentage of patients discon-
tinuing gabapentin due to side-effects were similar but
a greater number stopped the drug from inefficacy. A
much smaller percentage of patients in our study had a
greater than 50% reduction in seizure numbers reflect-
ing, in part, the severity of seizure disorders amongst
our population treated with gabapentin.
In our study, gabapentin appeared slightly more ef-
fective in the treatment of localization related seizures
as compared with the other drugs. This is likely to be
due to the high dose used in our center. The apparent
contradiction in the figures of efficacy and withdrawal
from lack of efficacy in gabapentin and lamotrigine is
due to the fact that a high percentage of patients who
had improved by 25% continued to take lamotrigine
and this data was not entered to calculate efficacy of
lamotrigine.
Topiramate has generally been considered to be a
highly effective drug. The meta-analysis of trials1 re-
ported in 1996 that the apparently most effective drug
topiramate generated an odds ratio twice that of the ap-
parently least effective drug gabapentin. However, the
highest dose used for gabapentin was only 1800 mg.
Another report6 in 1998 retrospectively compared
these five drugs in 105 patients and found that top-
iramate (30%) was the least likely to be withdrawn
from inefficacy as compared with gabapentin (54%) or
tiagabine (57%). In the same study, topiramate (26%),
however, was the commonest drug to be withdrawn
due to side-effects while for lamotrigine this was 19%,
gabapentin 21% and tiagabine and vigabatrin 14%
each. In our study, topiramate was stopped in 40%
of the patients as a result of side-effects. There was a
very high incidence of psychiatric and cognitive side-
effects amongst our patients. We have published these
results in an earlier report7.
In our analysis, topiramate appeared to be less ef-
fective but 93% of the patients had failed to benefit
from multiple new drugs previously suggesting that
these patients were very refractory to treatment. Our
study population had a similar number of withdrawals
from lack of efficacy as reported previously by Mor-
row8. The results for vigabatrin were more difficult to
assess as only a small number of patients were com-
menced on vigabatrin. Vigabatrin was initiated rather
cautiously and sparingly in our center due to previous
adverse experiences. Despite this, vigabatrin therapy
was associated with a high incidence of psychiatric
side-effects (16%) although no one was admitted to
hospital or developed a psychosis9.
An interesting observation in our group was severe
side-effects and worsening of seizures in three pa-
tients who were commenced on tiagabine and were al-
ready taking topiramate. This was evident within a few
weeks of commencement of tiagabine, before reaching
a daily dose of 20 mg. However, as the number is small
it is difficult to be certain whether there is a definite re-
lationship or if this was coincidental.
A retrospective analysis like this study is by no
means the best way to compare the effectiveness of
drugs but does give a picture of the problems that
are likely to be encountered in clinical practice, par-
ticularly with regard to side-effects. A recent study10
looked at patients with intractable epilepsy. Patients
were put on clobazam, vigabatrin, lamotrigine or
gabapentin as additional therapy. This study found that
out of 97 patients only 17% reported being ‘satisfied’
at 6 months. The operational definition for satisfaction
included >50% reduction of seizures, no experience
of side-effects/adverse events and improved quality of
life.
It has been suggested in journals such as the British
Medical Journal11 that gabapentin may not be as ef-
fective as the other new AEDs. Our data contradicts
this in that in this study it was the most effective in our
outpatient population. This may have been statistically
significant but a statistical significance was not calcu-
lated as this is a retrospective study and there was a
heterogeneous population group.
CONCLUSION
Of the five recently licensed antiepileptic drugs
(vigabatrin, lamotrigine, gabapentin, topiramate and
tiagabine), each one has proved beneficial as add-on
therapy in individual patients with refractory seizures
but differed in their side-effect profiles. Topiramate
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was associated with the highest incidence of side-
effects whilst lamotrigine and gabapentin were the
best tolerated. However, despite the poorer efficacy
figures for patients receiving the two most recently li-
censed drugs, topiramate and tiagabine, some patients
undoubtedly benefited and a few became seizure free
having failed previous therapies.
ACKNOWLEDGEMENTS
We would like to thank Dr S. Pope for his valuable
support in helping us with our paper.
FINANCIAL INTEREST
None.
REFERENCES
1. Marson, A. G., Kadir, Z. A. and Chadwick, D. W. New
antiepileptic drugs: a systemic review of their efficacy and tol-
erability. British Medical Journal 1996; 313: 1169–1174.
2. Wong, I. C. K., Chadwick, D. W., Mawer, G. E. W. and Sander,
J. W. A. S. Survey of the perceived efficacy and adverse drug
reaction profiles of Gabapentin, Lamotrigine and Vigabatrin.
Abstract. Epilepsia 1996; 37 (Suppl. 4): 80.
3. Schapel, G. and Chadwick, D. W. A survey comparing Lam-
otrigine and Vigabatrin in everyday clinical practice. Seizure
1996; 5: 267–270.
4. Rentmeester, Th. W., Gillisen, K., Scholtes, F. B. J.,
Kasteleijn-Nolst-Trenite´, D. G. A. and Schlosser, A. Surveil-
lance study of lamotrigine patients (aged ≥12 years) with re-
fractory epilepsy. Epilepsia 1998; 39 (Suppl. 2): 23.
5. Morris, G. L. Efficacy and tolerability of Gabapentin in clini-
cal practice. Clinical Therapeutics 1995; 17: 891–900.
6. Collins, T. L., Petroff, O. A. C. and Mattson, R. H. Com-
parison of new antiepileptic drug therapy. Epilepsia 1998; 39
(Suppl. 6): 59–60.
7. Crawford, P. M. An audit of topiramate use. Seizure 1998; 7:
207–212.
8. McDonnell, G. V. and Morrow, J. I. An audit of the new
antiepileptic drugs in clinical neurological practice. Seizure
1996; 5: 127–130.
9. Sander, J. W. A. S., Hart, Y. M., Trimble, M. R. and Shorvon,
S. D. Vigabatrin and psychosis. Journal of Neurology, Neuro-
surgery and Psychiatry 1991; 54: 435–439.
10. Selai, C. E. and Trimble, M. R. Adjunctive therapy in epilepsy
with new antiepileptic drugs: is it of any value. Seizure 1998;
7: 417–418.
11. Feely, M. Fortnightly review: drug treatment of epilepsy.
British Medical Journal 1999; 318: 106–109.
